News & Media
STATEMENT: MSMS Supports Executive Directive Aimed at Reducing Inulin Costs for Michigan Patients
The following is a public statement from Thomas Veverka, MD, FACS, president of the Michigan State Medical Society in response to Governor Whitmer issuing Executive Directive No. 2022-12 tasking State Department Directors with determining how to deliver generic, state-manufactured insulin at a lower cost to Michigan patients.
“The Michigan State Medical Society applauds Governor Whitmer for taking action to tackle a growing problem that’s currently affecting nearly one million Michigan patients, and that’s the exorbitantly high price of insulin. Today, more than 10 percent of Michigan residents live their lives with diabetes and all the costs that come along with that diagnosis, which for many are substantial considering the cost of insulin in the United States is nearly 10 times more than what it is in many other countries around the world.”
“That’s unacceptable. No patient should have to choose between feeding their families or buying insulin, between keeping the heat on or getting the medicine they need to survive. Hopefully, those sorts of decisions will become a thing of the past as our state leaders and policymakers work to find a way to manufacture this critical, live-saving medicine and lower its cost for Michigan’s many patients in need.”